medigraphic.com
ISSN 1561-302X (Print)

2022, Number 2

<< Back Next >>

Rev cubana med 2022; 61 (2)

Correlation between rapid and serum prostate-specific antigen tests

López HD, López SMÁ, Hernández EME, Chagoya TF

Language: Spanish
References: 34
Page: 1-16
PDF size: 429.29 Kb.


ABSTRACT

Introduction: To date, no consensus has been reached on the best approach for screening and early detection of Prostate Cancer (PCa) in the population. However, there are programs recommending the use of the rapid prostate-specific antigen test for the detection of PCa without a correlation analysis versus the serum test.
Objective: To identify the correlation between rapid and serum prostate specific antigen tests in the Mexican population.
Methods: A descriptive, cross-sectional and retrospective study was carried out, under a non-probabilistic convenience sampling from May 25 to July 13, 2017. The correlation coefficients of point biserial (rpb) and phi (rphi) were calculated.
Results: One thousand six hundred thirty five (1,635) records were included, mainly from Mexico City and the State of Mexico (n= 1,398; 85.5%, 95% CI 81-89.9). The average age was 51 years (SD= 7.68). The mean value of serum prostate antigen was 1.49 ng/ml (SD= 1.91). The proportion of men with positive rapid test (n=60; 3.7%; 95% CI 2.9-4.6) was lower (p= 0.0415) compared to the proportion of patients with a serum test ≥ 4 ng/ml (n= 85; 5.2%; 95% CI 4.1-6.3). The number of double negative cases was 1,530 (93.6%; CI95% 92.3-94.6) and of double positives was 40 (2.4%; CI95% 1.7-3.2). The point biserial and phi correlation coefficients showed low correlation between the rapid test and the serum prostate antigen test (rpb= 0.469; p < 0.001; r2= 0.2199 and rphi= 0.540; p < 0.001; r2= 0. 2916).
Conclusions: The rapid prostate-specific antigen test is a convenient tool for prostatic alteration detection programs in primary care medical units, where the serum test cannot be performed, however, as it is a test with low sensitivity and with low correlation coefficient with respect to serum prostate-specific antigen testing, this is an important point to consider when designing prostate cancer early detection programs.


REFERENCES

  1. Ramos G, Fullá JO. Detección precoz de cáncer de próstata. Rev. Médica Clínica Las Condes. 2013 [acceso: 10/02/2018];24(4):654-59. Disponible en: https://www.elsevier.es/es-revista-revista-medica-clinica-las-condes-202-articulo-deteccion-precoz-cancer-prostata-S07168640137020491.

  2. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi Lakeh M, MacIntyre MF, et al. The Global Burden of Cancer 2013. JAMA Oncol. 2015 [acceso: 10/02/2018];1(4):505-27. Disponible en: https://jamanetwork.com/journals/jamaoncology/fullarticle/22949662.

  3. Cayetano Alcaraz AA, Ramírez Rivera JA, Sotomayor de Zavaleta M, Castillejos Molina RA, Gabilondo Navarro F, Feria Bernal G, et al. Características de los casos incidentes de cáncer de próstata en los últimos 5 años en un hospital de tercer nivel en México. Revista Mexicana de Urología. 2016 [acceso: 06/02/2018];76(2):76-80. Disponible en: https://www.sciencedirect.com/science/article/pii/S20074085150015973.

  4. INEGI. Principales causas de mortalidad por sexo en el 2013. México 2015 [acceso: 18/02/2018]. Disponible en: http://www.inegi.org.mx/est/contenidos/proyectos/registros/vitales/consulta.asp?c=11800#.4.

  5. Yang Z, Yu L, Wang Z. PCA3, and TMPRSS2-ERG gene fusions as diagnostic biomarkers for prostate cancer. Chinese Journal of Cancer Research. 2016 [acceso: 18/02/2018];28(1):65-71. Disponible en: http://www.cjcrcn.org/article/html_9221.html5.

  6. Miano R, Mele GO, Germani S, Bove P, Sansalone S, Pugliese P F, et al. Evaluation of a new, rapid, qualitative, one-step PSA Test for prostate cancer screening: the PSA RapidScreen test. Prostate Cancer Prostatic Dis. 2005 [acceso: 18/02/2018];8(3):219-23. Disponible en https://www.nature.com/articles/45008026.

  7. Organización Panamericana de la Salud. Expertos regionales discuten enfoques para el tamizaje y detección temprana del cáncer de próstata en las Américas. Comunicado de prensa. [acceso: 18/02/2018] Disponible en: http://www.paho.org/hq/index.php?option=com_content&view=article&id=13818%3Aregional-experts-discuss-approaches-for-prostate-cancer-screening-and-early-detection-in-the-americas&catid=1872%3Acancer&Itemid=42459&lang=es7.

  8. OMS. Planificación. Control del cáncer: aplicación de los conocimientos. Guía de la OMS para desarrollar programas eficaces. Organización Mundial de la Salud. 2007 [acceso: 18/02/2018] Disponible en: http://apps.who.int/iris/bitstream/handle/10665/43690/9789243546995_spa.pdf;jsessionid=49443ACD446FF91525128933574FC0E1?sequence=18.

  9. OMS. Cuidados paliativos. Control del cáncer: aplicación de los conocimientos. Guía de la OMS para desarrollar programas eficaces. Organización Mundial de la Salud, 2010 [acceso: 18/02/2018] Disponible en: http://apps.who.int/iris/bitstream/handle/10665/44025/9789243547343_spa.pdf?sequence=19.

  10. OMS. Política y Abogacía. Control del cáncer: aplicación de los conocimientos. Guía de la OMS para desarrollar programas eficaces. Organización Mundial de la Salud, 2008 [acceso: 18/02/2018] Disponible en: http://apps.who.int/iris/bitstream/handle/10665/44013/9789243547527_spa.pdf?sequence=110.

  11. OMS. Detección temprana. Control del cáncer: aplicación de los conocimientos. Guía de la OMS para desarrollar programas eficaces. Organización Mundial de la Salud, 2007 [acceso: 18/02/2018] Disponible en: http://apps.who.int/iris/bitstream/handle/10665/44023/9789243547336_spa.pdf?sequence=111.

  12. OMS. Diagnóstico y tratamiento. Control del cáncer: aplicación de los conocimientos. Guía de la OMS para desarrollar programas eficaces. Organización Mundial de la Salud, 2008 [acceso: 18/02/2018] Disponible en: https://www.paho.org/hq/dmdocuments/2011/WHO-Cancer-Modules-Dg-Treatment.pdf12.

  13. Jalón Monzóna A, Escaf Barmadah S, Viña Alonso LM, Jalón Monzón M. Aspectos actuales sobre el cribado en el cáncer de próstata. SEMERGEN. Medicina de Familia. 2017 [acceso: 18/02/2018];43(5):387-93. Disponible en: https://www.elsevier.es/es-revista-medicina-familia-semergen-40-articulo-aspectos-actuales-sobre-el-cribado-S113835931630134413.

  14. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317(15):909-16.

  15. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994 [acceso: 20/02/2018];151(5):1283-90. Disponible en: https://pubmed.ncbi.nlm.nih.gov/7512659/15.

  16. Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990 [acceso: 18/02/2018];194:755-63. Disponible en: https://febs.onlinelibrary.wiley.com/doi/full/10.1111/j.1432-1033.1990.tb19466.x?sid=nlm%3Apubmed16.

  17. Lilja H, Christensson A, Dahlen U, Matikainen MT, Nilsson O, Pettersson K, et al. Prostate-specific antigen in serum occurs predominately in complex with a1-antichymotrypsin. Clin Chem 1991;37:1618-25.

  18. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and a1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51:222-26.

  19. Christensson A, Bjork T, Nilsson O, Dahlén U, Matikainen MT, Cockett AT, et al. Serum prostate specific antigen complexed to a1-antichymotrypsin as an indicator of prostate cancer. J Urol. 1993;150:100-5.

  20. Sokoll LJ, Chan DW. Total, free and complexed PSA: analysis and clinical utility. J Clin Ligand Assay 1998;21:171-79.

  21. Adhyam M, Gupta AK. A Review on the Clinical Utility of PSA in Cancer Prostate. Indian J Surg Oncol. 2012 [acceso: 18/02/2018];3(2):120-29. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392481/21.

  22. Schröder FH, Hugosson J, Roobol MJ, Tammela TLJ, Zappa M, Nelen V, et al. The European Randomized Study of Screening for Prostate Cancer - Prostate Cancer Mortality at 13 Years of Follow-up. Lancet. 2014 [acceso: 22/02/2018];384(9959):2027-35. Disponible en: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)60525-0/fulltext22.

  23. Littrup PJ, Kane RA, Mettlinet CJ, Murphy GP, Lee F, Toi A, et al. Cost-effective prostate cancer detection. Cancer 1994;74(12): 3146-58.

  24. Potter SR, Horniger W, Tinzl M, Bartsch G, Partin AW. Age, prostate-specific antigen, and digital rectal examination as determinants of the probability of having prostate cancer. Urology. 2001 [acceso: 20/02/2018];57(6):1100-104.Disponible en: https://www.goldjournal.net/article/S0090-4295(01)00980-3/fulltext24.

  25. Merrill RM, Stephenson RA. Trends in mortality rates in patients with prostate cancer during the era of prostate specific antigen screening. J Urol. 2000;163(2):503-10.

  26. Bartsch G, Horninger W, Klocker H, Reissigl A, Oberaigner W, Schönitzer D, et al. Prostate cancer mortality after the introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology. 2001;58(3):417-24.

  27. Meyer F, Moore L, Bairati I, Fradet Y. Downward trend in prostate cancer mortality in Quebec and Canada. J Urol. 1999;161(4):1189-191.

  28. Tarone RE, Chu KC, Brawley OW. Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology. 2000;11(2):167-170.

  29. Martín E, Luján M, Sánchez E, Herrero A, Páez A, Berenguer A. Final results of a screening campaign for prostate cancer. Eur Urol. 1999;35:26-31.

  30. Gustafsson O, Norming U, Almgard LE, Fredriksson A, Gustavsson G, Harvig B, et al. Diagnostic methods in the detection of prostate cancer. A study of a randomly selected population of 2,400 men. J Urol. 1992;148(6):1827-31.

  31. Horninger W, Reissigl A, Rogatsch H, Volgger H, Studen M, Klocker H, et al. Prostate carcinoma screening in the county of Tyrol, Austria: experience and results. Cancer. 1997;80(9):1818-29.

  32. Berg W, Linder C, Eschholz G, Schubert J. Pilot study of the practical relevance of a one-step test for prostate-specific antigen in capillary blood to improve the acceptance rate in the early detection program of prostate carcinoma. Int Urol Nephrol. 2001;32:381-8.

  33. Pron G. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis. Ont Health Technol Assess Ser. 2015 [acceso: 20/02/2018];15(10):1-64. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4561549/#33.

  34. Serrano de la Cruz Torrijos F, López Alcina E, Juan Escudero JU, Fabuel Deltoro M, Montoliu García A, Real Romaguera A, et al. Detección sérica de PSA mediante un test rápido (SD Bioline PSA). Arch. Esp. Urol. 2008;61(6):685-90.




2020     |     www.medigraphic.com